Find clinical trials for Eczema in Barcelona, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Eczema trials near Barcelona, CT, ESP:
The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may h...
Phase 3
Barcelona, Spain and 39 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Barcelona, Spain and 76 other locations
The main purpose of this study is to evaluate the effectiveness and safety of 24 weeks of lebrikizumab in improving disease severity, signs, and symp...
Phase 3
Barcelona, Spain and 3 other locations
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...
Phase 3
Esplugues de Llobregat, Barcelona [Barcelona], Spain and 78 other locations
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...
Phase 3
Esplugues de Llobregat, Barcelona [Barcelona], Spain and 97 other locations
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...
Phase 3
Esplugues de Llobregat, Barcelona [Barcelona], Spain and 95 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Barcelona, Spain and 101 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Barcelona, Cataluña, Spain and 234 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Barcelona, Spain and 560 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Barcelona, Spain and 320 other locations
Clinical trials
Research sites
Resources
Legal